FDA and EU approval Leverage ZYNLONTA’s approved status and ongoing development to position partnerships with biopharma companies seeking ADC capabilities in late-stage and combination therapies, targeting diffuse large B-cell lymphoma markets and potential indications in earlier lines.

Manufacturing and ADC expertise Highlight ADC Therapeutics’ end-to-end capabilities from clinical development to manufacturing and commercialization to attract sponsors looking for integrated ADC expertise, process development, and scalable production solutions.

Strategic financings and growth Use recent PIPE financing and investor activity to approach potential co-development or strategic financing partners, especially those seeking exposure to oncology biologics and innovative ADC platforms.

Global footprint Emphasize the Lausanne base with U.S. operations as a global hub for collaboration, manufacturing partnerships, and clinical programs to engage multinational pharma companies seeking cross-border development and commercialization opportunities.

Pipeline and future potential Position the upcoming PSMA-targeting ADC and IND-enabling programs as opportunities for tiered collaborations, licensing deals, or milestone-driven partnerships with firms seeking next-generation ADC assets beyond ZYNLONTA.